Trial Outcomes & Findings for Prevention of Post Operative Bone Loss in Children (NCT NCT00655681)

NCT ID: NCT00655681

Last Updated: 2023-08-22

Results Overview

Mean change lumbar spine post-op BMD Mean Right metaphyseal femur change post op BMD Mean Right transitional femur change post op BMD Mean Right diaphyseal femur change post op BMD Mean Left metaphyseal femur change post op BMD Mean Left transitional femur change post op BMD Mean Left diaphyseal femur change post op BMD

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

24 participants

Primary outcome timeframe

Preoperative to post-operative DXA scan (4-12 weeks)

Results posted on

2023-08-22

Participant Flow

Between 2007 and 2011, twenty-four subjects were enrolled, and 20 were included in the final analysis (2 subjects were not administered drug due to slightly low serum calcium, and two did not return for the final dual energy x-ray absorptiometry (DXA) scan). There were 11 subjects randomized into the treatment group and 9 into the control group.

2 subjects were not administered drug due to slightly low serum calcium, and two did not return for the final DXA scan

Participant milestones

Participant milestones
Measure
A Patients Receiving Pamidronate
Receives pamidronate 1mg/kg IV once during the post operative period. Pamidronate is given over 4 hours.
B Patients Receiving Saline (Control Placebo)
receives saline injection IV once in the post operative period in addition to routine post operative fluids.
Overall Study
STARTED
12
10
Overall Study
COMPLETED
11
9
Overall Study
NOT COMPLETED
1
1

Reasons for withdrawal

Reasons for withdrawal
Measure
A Patients Receiving Pamidronate
Receives pamidronate 1mg/kg IV once during the post operative period. Pamidronate is given over 4 hours.
B Patients Receiving Saline (Control Placebo)
receives saline injection IV once in the post operative period in addition to routine post operative fluids.
Overall Study
Lost to Follow-up
1
1

Baseline Characteristics

Prevention of Post Operative Bone Loss in Children

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
A: Recieved Pamidronate 1mg/kg
n=11 Participants
Receives pamidronate 1mg/kg IV once. The pamidronate is mixed 1 to 10 (10 cc of saline for each 1 mg pamidronate), with a minimum volume of 50 cc saline. The medication is administered as an IV infusion to run at a rate beginning at 20 cc/hr, adjusting the rate so that the infusion will run over 4 hours. For children \< 8 kg (80cc infusion), the rate would be 20 cc/hr and the duration would be determined by the volume.
B: Receives Saline 10cc/kg
n=9 Participants
receives saline injection IV once 10cc/kg over 4 hours post operatively in addition to routine post operative fluids
Total
n=20 Participants
Total of all reporting groups
Age, Continuous
9.1 years
n=5 Participants
7.8 years
n=7 Participants
8.5 years
n=5 Participants
Age, Categorical
<=18 years
11 Participants
n=5 Participants
9 Participants
n=7 Participants
20 Participants
n=5 Participants
Age, Categorical
Between 18 and 65 years
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Age, Categorical
>=65 years
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Sex: Female, Male
Female
4 Participants
n=5 Participants
8 Participants
n=7 Participants
12 Participants
n=5 Participants
Sex: Female, Male
Male
7 Participants
n=5 Participants
1 Participants
n=7 Participants
8 Participants
n=5 Participants
Region of Enrollment
United States
11 participants
n=5 Participants
9 participants
n=7 Participants
20 participants
n=5 Participants

PRIMARY outcome

Timeframe: Preoperative to post-operative DXA scan (4-12 weeks)

Mean change lumbar spine post-op BMD Mean Right metaphyseal femur change post op BMD Mean Right transitional femur change post op BMD Mean Right diaphyseal femur change post op BMD Mean Left metaphyseal femur change post op BMD Mean Left transitional femur change post op BMD Mean Left diaphyseal femur change post op BMD

Outcome measures

Outcome measures
Measure
A Patients Receiving Pamidronate
n=11 Participants
Receives pamidronate 1mg/kg one time post operatively over 4 hours
B Patients Receiving Saline (Control Placebo)
n=9 Participants
receives saline injection once 10 cc/kg over 4 hours in additional to routine post op fluide
Amount of Bone Density Lost (%) From pre-to Post-operative DXA Scan
0.043 percent change
Standard Deviation 0.04
-0.025 percent change
Standard Deviation 0.02

Adverse Events

A: Receives Pamidronate 1mg/kg

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

B: Receives Saline 10cc/kg Over 4 Hours Post Operatively

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Elizabeth A. Szalay MD

University of New Mexico Carrie Tingley Hospital

Phone: 505 272-5214

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place